SCHEMBL2256197

SCHEMBL2256197

CN(C)c1ccc(NC(=O)COc2cc(C(F)(F)F)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
TGFBR1 P36897 1/20 0.45
MAPT P10636 6/20 0.43
HTT P42858 1/20 0.43
P2RY1 P47900 3/20 0.43
HPGD P15428 3/20 0.42
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
PTGS2 P35354 1/20 0.40
CASP3 P42574 1/20 0.40
KDM4E B2RXH2 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
GFER P55789 1/20 0.39
THRB P10828 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2262095 0.91 ALDH1A1 (0.47) ALDH1A1TGFBR1MAPTHTTP2RY1
SCHEMBL2258261 0.90 KDM4E (0.47) ALDH1A1TGFBR1MAPTHTTP2RY1
SCHEMBL2259102 0.90 TGFBR1 (0.47) ALDH1A1TGFBR1MAPTP2RY1HPGD
SCHEMBL2260618 0.90 HPGD (0.46) ALDH1A1TGFBR1P2RY1HPGDSMN1; SMN2
SCHEMBL2257314 0.90 TGFBR1 (0.47) ALDH1A1TGFBR1P2RY1POLBCASP3
SCHEMBL2258078 0.89 TGFBR1 (0.44) ALDH1A1TGFBR1P2RY1POLBSMN1; SMN2
SCHEMBL2257201 0.89 TGFBR1 (0.45) ALDH1A1TGFBR1P2RY1HPGDCASP3
SCHEMBL2259123 0.89 KDM4E (0.47) ALDH1A1TGFBR1MAPTP2RY1HPGD
SCHEMBL2263535 0.89 KCNJ5 (0.48) ALDH1A1TGFBR1MAPTP2RY1SMN1; SMN2
SCHEMBL2258576 0.88 TGFBR1 (0.46) ALDH1A1TGFBR1MAPTP2RY1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121621-B1 LXR AND FXR MODULATORS EXELIXIS PATENT CO LLC (US) 2014-05-07 EP disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 ALDH1A1 3692/4885TGFBR1 481/4885MAPT 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.